Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis

Hypertension

Volumn 64, Issue 3, 2014, Pages 619-625

  Pulgar, Victor M ^a,c   Yamaleyeva, Liliya M ^b   Varagic, Jasmina ^b   McGee, Carolynne M ^b   Bader, Michael ^d,e   Dechend, Ralf ^e   Howlett, Allyn C ^a   Brosnihan, K Bridget ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Hypertension and Vascular Research Center   (United States)

^c WINSTON SALEM STATE UNIVERSITY   (United States)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Endocannabinoids; Fatty acid amide hydrolase; High risk pregnancy; Monoacylglycerol lipases

Indexed keywords

ACYLGLYCEROL LIPASE; ANGIOTENSIN II; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; INDOMETACIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM; ENZYME LOCALIZATION; FEMALE; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; NONHUMAN; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TRANSGENIC RAT; UTERINE ARTERY; UTERUS CONTRACTION;

ENDOCANNABINOIDS; FATTY-ACID AMIDE HYDROLASE; HIGH-RISK PREGNANCY; MONOACYLGLYCEROL LIPASES;

AMIDOHYDROLASES; ANGIOTENSIN II; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BENZODIOXOLES; BLOOD PRESSURE; CARBAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; HYDROLYSIS; HYPERTENSION, PREGNANCY-INDUCED; MALE; MONOGLYCERIDES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PREGNANCY; PREGNANCY, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; UTERINE ARTERY; VASOCONSTRICTION;

EID: 84907598042     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03633     Document Type: Article

References (56)

1. Herr D, Bekes I, Wulff C. Local renin angiotensin system in the reproductive system: A review of literature. Front Endocrinol. 2013;4:150. doi: 10.3389/fendo.2013.00150.
2. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52:2682-2689.
3. Gant NF, Whalley PJ, Everett RB, Worley RJ, MacDonald PC. Control of vascular reactivity in pregnancy. Am J Kidney Dis. 1987;9:303-307.
4. Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension. 2010;55:1239-1245.
5. Bohlender J, Ganten D, Luft FC. Rats transgenic for human renin and human angiotensinogen as a model for gestational hypertension. J Am Soc Nephrol. 2000;11:2056-2061.
6. Verlohren S, Niehoff M, Hering L, Geusens N, Herse F, Tintu AN, Plagemann A, LeNoble F, Pijnenborg R, Muller DN, Luft FC, Dudenhausen JW, Gollasch M, Dechend R. Uterine vascular function in a transgenic preeclampsia rat model. Hypertension. 2008;51:547-553.
7. Herse F, Lamarca B, Hubel CA, et al. Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation. 2012;126:2990-2999.
8. 2. Pharmacol Rev. 2010;62:588-631.
9. Sun X, Xie H, Yang J, Wang H, Bradshaw HB, Dey SK. Endocannabinoid signaling directs differentiation of trophoblast cell lineages and placentation. Proc Natl Acad Sci U S A. 2010;107:16887-16892.
10. Abán C, Leguizamón GF, Cella M, Damiano A, Franchi AM, Farina MG. Differential expression of endocannabinoid system in normal and preeclamptic placentas: effects on nitric oxide synthesis. Placenta. 2013;34:67-74.
11. Fonseca BM, Correia-da-Silva G, Almada M, Costa MA, Teixeira NA. The endocannabinoid system in the postimplantation period: A role during decidualization and placentation. Int J Endocrinol. 2013;2013:510540.
12. Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, Morrison JJ. Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol. 2004;190:2-9; discussion 3A.
13. Cotterill RW, Penney LL, Vaughn DL, Reimann BE, Rauls DO. Acute cardiovascular effects of delta-9-tetrahydrocannabinol in pregnant anesthetized sheep. Biol Res Pregnancy Perinatol. 1984;5:1-5.
14. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful pregnancy. Nat Med. 2012;18:1754-1767.
15. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A. 1999;96:5802-5807.
16. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83-87.
17. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99:10819-10824.
18. Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 2007;14:237-246.
19. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA. 2009;106:20270-20275.
20. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: A new target for anti-anxiety drugs? Trends Mol Med. 2003;9:474-478.
21. Feledziak M, Lambert DM, Marchand-Brynaert J, Muccioli GG. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis. Recent Pat CNS Drug Discov. 2012;7:49-70.
22. Wang H, Xie H, Guo Y, Zhang H, Takahashi T, Kingsley PJ, Marnett LJ, Das SK, Cravatt BF, Dey SK. Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest. 2006;116:2122-2131.
23. Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Bell SC, Konje JC, Teixeira NA. The endocannabinoid 2-arachidonoylglycerol (2-AG) and metabolizing enzymes during rat fetoplacental development: A role in uterine remodelling. Int J Biochem Cell Biol. 2010;42:1884-1892.
24. Szekeres M, Nádasy GL, Turu G, Soltész-Katona E, Tóth ZE, Balla A, Catt KJ, Hunyady L. Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem. 2012;287:31540-31550.
25. Pulgar VM, Yamashiro H, Rose JC, Moore LG. Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestation. J Renin Angiotensin Aldosterone Syst. 2011;12:176-183.
26. Pulgar VM, Figueroa JP. Antenatal betamethasone administration has a dual effect on adult sheep vascular reactivity. Pediatr Res. 2006;60:705-710.
27. Nguyen DH, Zhou T, Shu J, Mao JH. Quantifying chromogen intensity in immunohistochemistry via reciprocal intensity. Cancer InCytes. 2013;2:.
28. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005;45:742-746.
29. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26:1629-1635.
30. Zhang S, Zheng R, Yang L, Zhang X, Zuo L, Yang X, Bai K, Song L, Tian J, Yang J, Liu H. Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction. J Cell Physiol. 2013;228:142-148.
31. Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension. 2011;58:77-84.
32. Brewer J, Liu R, Lu Y, Scott J, Wallace K, Wallukat G, Moseley J, Herse F, Dechend R, Martin JN Jr, Lamarca B. Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension. 2013;62:886-892.
33. Herse F, Staff AC, Hering L, Müller DN, Luft FC, Dechend R. AT1-receptor auto antibodies and uteroplacental RAS in pregnancy and preeclampsia. J Mol Med (Berl). 2008;86:697-703.
34. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids. 2004;70:223-232.
35. Walsh SW. Preeclampsia: An imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol. 1985;152:335-340.
36. Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ 2nd, Clemens JD, Hauth JC, Catalano P, Sibai B, Curet LB, Levine RJ. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: A multicenter prospective study. JAMA. 1999;282:356-362.
37. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000;294:27-32.
38. Ho WS, Randall MD. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol. 2007;150:641-651.
39. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009;5:37-44.
40. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006;12:21-38.
41. Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, Hammock BD. Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. Br J Pharmacol. 2007;152:691-698.
42. Czikora Á, Lizanecz E, Boczán J, Daragó A, Papp Z, Édes I, Tóth A. Vascular metabolism of anandamide to arachidonic acid affects myogenic constriction in response to intraluminal pressure elevation. Life Sci. 2012;90:407-415.
43. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol. 1998;274(1 pt 2):H375-H381.
44. Mukhopadhyay S, Chapnick BM, Howlett AC. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol. 2002;282:H2046-H2054.
45. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther. 2007;321:930-937.
46. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol. 2006;147:917-925.
47. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
48. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agrò A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem. 2000;275:13484-13492.
49. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411-432.
50. Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev. 2013;65:849-871.
51. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem. 1997;272:27218-27223.
52. Kagota S, Yamaguchi Y, Nakamura K, Sugiura T, Waku K, Kunitomo M. 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. Eur J Pharmacol. 2001;415:233-238.
53. Wang H, Xie H, Sun X, Kingsley PJ, Marnett LJ, Cravatt BF, Dey SK. Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation. Prostaglandins Other Lipid Mediat. 2007;83:62-74.
54. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, Marnett LJ. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877-44885.
55. Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther. 2008;120:71-80.
56. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389-462.